Another study suggested that patients with NSCLC and increased plasma cell signatures treated with anti-PD-1/anti-PD-L1 therapy displayed good survival, regardless of CD8+ T-cell infiltration [37]. Here, CD8A is linked to non-small cell lung carcinoma.